Alzheimer’s disease symptoms usually begin quietly: a repeated question, a misplaced set of keys, a familiar recipe that suddenly feels confusing. Because those changes overlap with ordinary aging, poor sleep, depression, thyroid problems and vitamin deficiencies, the first job of a medical work-up is not to confirm Alzheimer’s disease. It is to look carefully at everything else the symptoms could be. That work-up has changed, because a blood test able to detect Alzheimer’s-related protein changes now carries clearance from the U.S. Food and Drug Administration. In this article you’ll learn how Alzheimer’s disease symptoms progress, what drives them, which routine laboratory tests rule out reversible causes, what the new blood biomarkers can and cannot tell you, and how today’s treatments perform.
What Alzheimer’s disease is, and how it differs from dementia
Dementia is an umbrella term. It describes a decline in memory, language, reasoning or judgment severe enough to interfere with daily life. Alzheimer’s disease is the single most common cause of that decline, accounting for roughly six to eight of every ten cases according to the Centers for Disease Control and Prevention. Other causes include vascular dementia, Lewy body dementia and frontotemporal dementia, and many older adults have more than one process at the same time.
What changes inside the brain
Two protein changes define Alzheimer’s disease under the microscope. Fragments of a protein called beta-amyloid clump together outside brain cells into deposits known as plaques. A second protein, tau, becomes abnormally modified and twists into tangles inside the cells. Nerve connections weaken, brain tissue shrinks in the regions that store new memories, and Alzheimer’s disease symptoms gradually appear. These changes begin years, sometimes more than a decade, before anyone notices a problem — which is why the timing of testing matters so much.
Alzheimer’s disease symptoms, stage by stage
Alzheimer’s disease symptoms progress along a broad arc, but the pace differs enormously from person to person. Some people remain independent for years after diagnosis. Stages are a communication tool for families and clinicians, not a countdown, and the distinction from ordinary aging is one of pattern and progression rather than a single incident.
Early stage
Short-term memory is affected first. People repeat questions, lose track of recent conversations, misplace items in unusual places, and struggle with planning, budgeting or multi-step tasks. Word-finding pauses appear. Many people notice these changes themselves and compensate quietly, which is one reason diagnosis is delayed.
Moderate stage
Memory gaps widen to include personal history, confusion about time and place grows, and getting lost in a familiar neighborhood becomes possible. Sleep patterns invert, agitation may appear in the late afternoon, and help is needed with dressing, cooking and medication.
Later stage
Communication becomes limited, recognition of close family may fade, and physical abilities such as walking and swallowing decline. Care needs are continuous. Dignity, comfort, familiar routines and pain control become the central goals of care.
| Common with ordinary aging | Worth a medical appointment |
|---|---|
| Forgetting a name, then remembering it later | Forgetting the names of people seen every week |
| Misplacing glasses occasionally | Finding items in odd places and being unable to retrace steps |
| Needing a moment to find a word | Substituting wrong words so often that conversation stalls |
| Making an occasional error in the checkbook | No longer being able to follow a monthly budget |
| Feeling tired of routines | Withdrawing from hobbies and social life over several months |
Causes and risk factors
Age and genetics
Age is the strongest risk factor by a wide margin. Genetics adds a second layer. A gene called APOE comes in several versions, and the version known as APOE4 raises the likelihood of developing Alzheimer’s disease, particularly in people who inherit it from both parents. It is a risk factor, not a verdict: many APOE4 carriers never develop dementia, and many people with Alzheimer’s disease carry no copy at all. Rare inherited mutations cause a small number of cases that begin before age 65.
Risk factors you can act on
The CDC reports that a substantial share of dementia cases could be prevented or delayed by addressing modifiable risks. What is good for blood vessels appears to be good for the brain: untreated high blood pressure, diabetes, smoking, physical inactivity, midlife obesity, excessive alcohol, hearing loss, head injury, depression and social isolation all appear on that list. Several are visible in routine laboratory work. People managing blood sugar rely on a glycated hemoglobin test, and vascular prevention tracks an LDL cholesterol level.
How Alzheimer’s disease is diagnosed today
There is no single test that diagnoses Alzheimer’s disease. A diagnosis is assembled from a history taken with a family member present, a physical and neurological examination, structured memory and thinking tests, laboratory work, and usually brain imaging. Biomarker testing is added when the clinical picture is unclear or when treatment decisions depend on it.
The routine lab panel that looks for reversible causes
Before anyone talks about amyloid, a doctor rules out conditions that can imitate Alzheimer’s disease symptoms and that often improve once treated. This is the most useful blood work most patients will ever have, and it is inexpensive and widely available. A standard work-up checks thyroid function with a thyroid stimulating hormone test, because an underactive thyroid can produce slowed thinking, apathy and forgetfulness; readers can review a full guide to hypothyroidism. It measures a vitamin B12 blood level, since deficiency causes memory and balance problems that can partly reverse with treatment. It includes a complete blood count to detect anemia or infection.
A basic metabolic panel completes the picture. It reports a sodium level, because low sodium is a classic and correctable cause of confusion in older adults. It reports a creatinine value for kidney function, and it reports a total calcium measurement, since high calcium can cause confusion and low mood. Glucose, liver enzymes and, in some settings, tests for syphilis or HIV may be added. Some clinicians also order a homocysteine measurement when a B-vitamin problem is suspected. None of these tests diagnoses Alzheimer’s disease. They exist to make sure nothing treatable is missed first.
Cognitive testing and imaging
Brief office tests screen for a problem; longer neuropsychological testing maps which abilities are affected. An MRI or CT scan looks for strokes, tumors, bleeding and fluid on the brain, and shows the pattern of shrinkage. Specialized PET scans visualize amyloid or tau directly, and a lumbar puncture measures the same proteins in spinal fluid. Both are accurate, and both are costly, limited in availability and unappealing to many patients. That is the gap blood tests are meant to close.
Blood biomarkers: what a p-tau217 test can and cannot tell you
What these tests actually measure
The most useful blood marker so far is a modified form of the tau protein called p-tau217, sometimes measured on its own and sometimes as a ratio against a beta-amyloid fragment. A high result suggests that the amyloid and tau changes typical of Alzheimer’s disease are present in the brain. Notice the wording: these tests detect the biology of Alzheimer’s disease. They do not measure memory or disability, and they do not tell you which stage someone is in.
The first FDA-cleared blood test
In May 2025 the FDA cleared the first blood test used in diagnosing Alzheimer’s disease, a plasma ratio combining p-tau217 and beta-amyloid 1-42. Its authorized use is narrow and worth reading closely. According to the agency’s own announcement of the first cleared Alzheimer’s blood test, it is intended for adults aged 55 and older who already show signs and symptoms of cognitive decline, who are being assessed in a specialized care setting, and it is explicitly not intended as a screening test or as a stand-alone diagnosis.
Why this is not a screening test for healthy people
The reason is statistical rather than technical. In a memory clinic, most people tested genuinely have a memory problem, so an abnormal result usually means what it appears to mean. Among people with no symptoms, amyloid changes are common and often never progress to dementia in that person’s lifetime. A positive result there would frequently label someone who will remain well, with real consequences for anxiety and identity, and no treatment is currently offered to people without symptoms. Professional guidance published in 2025 restricts these tests to the work-up of people with measurable cognitive impairment, assessed by clinicians trained in memory disorders. Direct-to-consumer testing outside that pathway is not recommended.
What a result means, and what it does not
A clearly abnormal result in someone with memory symptoms makes Alzheimer’s disease the most likely explanation and can spare that person a spinal tap or a PET scan. A clearly normal result makes Alzheimer’s disease unlikely and redirects the search toward other causes, which is often the more valuable outcome. Results in between exist: laboratories increasingly use two thresholds with an intermediate zone, and a result landing in that zone means confirmatory testing rather than a conclusion. Kidney disease and body weight can shift these values, so results are read in context.
Because a laboratory report is easy to misread on its own, BloodSense provides a plain-language blood test analyzer, and one companion article explains abnormal blood test results in people who feel fine.
Treatment options, described honestly
Anti-amyloid antibody therapies
Lecanemab and donanemab are laboratory-made antibodies given by infusion that clear amyloid from the brain. They are approved for early Alzheimer’s disease only — mild cognitive impairment or mild dementia — and confirmation of amyloid is mandatory before starting. In the pivotal trials, decline over eighteen months was slower in treated participants than in those given placebo, but the difference was modest: a slowing of the slope, not a reversal, and small enough that families may or may not notice it. That trade-off deserves a frank conversation rather than a headline.
The main safety concern is a group of side effects called amyloid-related imaging abnormalities, or ARIA — swelling or small spots of bleeding in the brain seen on MRI. Most cases cause no symptoms and settle when treatment is paused, but a small number are serious and rare cases have been fatal. Monitoring is therefore built into treatment: an MRI before the first dose and repeat scans at set intervals. Risk is higher in people who carry APOE4, especially two copies, so genetic testing is recommended before treatment so that the conversation about risk is an informed one. People taking blood thinners are generally not candidates. Mayo Clinic maintains a practical overview of Alzheimer’s disease diagnosis and treatment.
Medications for symptoms
Cholinesterase inhibitors such as donepezil, rivastigmine and galantamine, and memantine for moderate to severe disease, remain part of standard care. They do not change the underlying disease, but they can modestly support memory, attention and daily function for a period, and they are inexpensive.
Care that is not a prescription
Structured routines, orientation cues, treatment of pain, correction of hearing and vision, physical activity, good sleep and social contact all reduce agitation and support function. Caregiver education and respite are not optional extras: they are among the interventions with the strongest evidence for keeping people at home longer.
Reducing risk and knowing when to seek help
What the evidence supports
No supplement, diet or brain-training program has been shown to prevent Alzheimer’s disease symptoms. What large studies do support is unglamorous: treat high blood pressure, manage diabetes and cholesterol, stay physically active, avoid smoking, limit alcohol, correct hearing loss, protect the head, treat depression, sleep adequately and stay socially engaged. These measures also reduce stroke and heart disease, so the effort is never wasted.
When to see a doctor
Book an appointment when memory or thinking changes are noticed by other people, have progressed over several months, interfere with work, finances, driving or medication, or come with personality change, apathy or withdrawal. Seek prompt medical attention for confusion that appears over hours or days, which usually signals infection, medication effects or dehydration rather than Alzheimer’s disease. Bring a medication list and a family member who can describe what has changed.
Latest scientific advances
Research on blood testing has moved quickly. Here is what the recent evidence says, and what it means in practice.
Blood testing now has formal clinical guidance
In 2025 the Alzheimer’s Association published a clinical practice guideline on blood-based biomarkers, built on a systematic review — a structured summary of all the studies on a question. It recommends these tests within specialized care, for people who already have measurable problems with memory or thinking. What this means for you: if a doctor proposes a blood biomarker test, it belongs in an assessment of real symptoms, not in a check-up for someone who feels well.
The best blood markers now rival spinal fluid testing
A 2025 systematic review and meta-analysis — a study that pools results from many earlier studies — in The Lancet Neurology found that the strongest plasma p-tau tests identify Alzheimer’s biology about as reliably as spinal fluid testing, with p-tau217 the clear leader. A separate pooled analysis published in 2024 reached the same conclusion for both amyloid and tau changes. What this means for you: for many people, a blood draw can now answer a question that used to require a lumbar puncture or a PET scan, which makes an accurate answer easier to obtain.
Blood tests outperform first impressions in everyday practice
Two large studies in primary and specialist clinics, published in JAMA in 2024 and in Nature Medicine in 2025, used cut-off values fixed in advance — the rules were set before patients were tested, which is the honest way to do it. In both, the blood test identified Alzheimer’s-related changes more reliably than the initial clinical impression recorded before biomarker results were available. What this means for you: these tests are most valuable where diagnostic uncertainty is highest, and they support a clinician’s judgment rather than replacing it.
Results are not always yes or no
A 2025 study of the p-tau217 to beta-amyloid ratio in clinic and community groups found that using two thresholds, with an intermediate band between them, improved reliability — at the cost of leaving some people with an inconclusive result. What this means for you: an in-between result is a normal part of how these tests work, not a laboratory error, and it calls for follow-up rather than alarm.
Anti-amyloid treatment: real but modest, and monitored closely
The phase 3 trial of lecanemab, published in the New England Journal of Medicine in 2023, showed less decline over eighteen months in treated participants than in those given placebo, alongside a clear reduction in brain amyloid. Brain swelling or small bleeds appeared in roughly one participant in eight, and infusion reactions in about one in four.
Expert use recommendations published the same year advise MRI monitoring, APOE genetic testing beforehand because APOE4 carriers face a higher risk of these brain changes, and avoidance in people on anticoagulants. What this means for you: this is a treatment with a genuine but limited effect that requires eligibility testing, regular scans and a realistic conversation about goals — still an early chapter, not a cure.
Glossary
| Term | Definition |
|---|---|
| Beta-amyloid | A protein fragment that clumps into deposits called plaques outside brain cells. Its build-up is one of the two defining features of Alzheimer’s disease. |
| Tau and p-tau217 | Tau is a protein inside nerve cells that twists into tangles in Alzheimer’s disease. P-tau217 is a chemically modified form of tau that can be measured in blood. |
| Biomarker | A measurable biological signal, such as a protein in blood, used to detect or track a disease process. |
| Plasma | The clear liquid part of blood left once the cells are removed. Most Alzheimer’s blood biomarkers are measured in plasma. |
| APOE4 | A common version of the APOE gene that raises the risk of Alzheimer’s disease and of side effects from anti-amyloid treatment. It is a risk factor, not a diagnosis. |
| ARIA | Amyloid-related imaging abnormalities: swelling or small areas of bleeding in the brain seen on MRI during anti-amyloid treatment. Often causes no symptoms, but it requires monitoring. |
| Mild cognitive impairment | Measurable difficulty with memory or thinking that does not yet prevent independent daily life. It may or may not progress to dementia. |
| PET scan | Positron emission tomography, an imaging test that uses a tracer to show amyloid or tau deposits in the living brain. |
| Cerebrospinal fluid | The fluid surrounding the brain and spinal cord, sampled by lumbar puncture, in which the same proteins can be measured. |
| Cholinesterase inhibitor | A class of medicines, including donepezil and rivastigmine, that supports communication between nerve cells and can ease symptoms for a time. |
Frequently asked questions
Is there a blood test for Alzheimer’s disease?
Yes, but with important limits. A plasma test combining p-tau217 and a beta-amyloid fragment received FDA clearance in May 2025 for adults aged 55 and older who already show signs of cognitive decline and are being evaluated in a specialized care setting. It detects the protein changes associated with Alzheimer’s disease; it does not by itself make a diagnosis, and it is not a screening test for people without symptoms. Other laboratory-developed p-tau217 tests are also in clinical use. Access, cost and insurance coverage still vary widely, and a physician orders and interprets the result within a full assessment.
At what age do Alzheimer’s disease symptoms usually start?
Most people develop noticeable symptoms after age 65, and risk climbs steadily with each decade after that. A small minority — generally fewer than one in twenty cases — have early-onset disease that begins in the forties, fifties or early sixties, sometimes linked to a rare inherited mutation. Symptoms starting before 65 deserve specialist assessment, partly because other conditions become relatively more likely at younger ages.
What is the difference between Alzheimer’s disease and dementia?
Dementia describes the symptoms: a decline in memory and thinking severe enough to disrupt daily life. Alzheimer’s disease is one specific cause of those symptoms, and the most common one. Saying someone has dementia is like saying they have a fever; identifying Alzheimer’s disease, vascular disease or Lewy body disease names the reason behind it. The distinction matters because causes differ in their course, their treatments and the safety precautions they require.
Can a vitamin deficiency cause symptoms that look like Alzheimer’s disease?
It can. Vitamin B12 deficiency is the best known example and can cause forgetfulness, slowed thinking, mood change and unsteadiness, sometimes improving substantially once corrected. Thyroid disease, low sodium, high calcium, kidney or liver problems, depression, poor sleep, alcohol and certain medications can all mimic early Alzheimer’s disease symptoms. This is precisely why a basic laboratory panel comes first in the work-up, before anyone considers biomarker testing.
Should I order an Alzheimer’s blood test for myself?
Current professional guidance does not support testing outside a clinical evaluation. In people without symptoms, an abnormal result frequently reflects changes that will never cause dementia in that person’s lifetime, and there is no approved treatment for people without symptoms. If you are concerned about memory, the appropriate first step is a medical appointment, where an examination, cognitive testing and routine blood work will determine whether biomarker testing is useful at all.
Do the new treatments stop Alzheimer’s disease?
No. Lecanemab and donanemab remove amyloid and slow the rate of decline over about eighteen months in people with early disease, but they do not halt it, reverse it or restore lost abilities. They require confirmed amyloid, regular infusions, MRI monitoring for brain swelling or bleeding, and genetic testing to assess risk. For many people the decision comes down to a modest, uncertain benefit weighed against real burden and risk, which is a personal judgment made with a specialist.
Sources
- U.S. Food and Drug Administration — FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease, 2025 — fda.gov
- Centers for Disease Control and Prevention — About Dementia, 2024 — cdc.gov
- Mayo Clinic — Alzheimer’s disease: Diagnosis and treatment — mayoclinic.org
- Palmqvist S, et al. — Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings — Alzheimer’s & Dementia, 2025 — doi.org/10.1002/alz.70535
- Therriault J, et al. — Blood phosphorylated tau for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis — The Lancet Neurology, 2025 — doi.org/10.1016/S1474-4422(25)00227-3
- Khalafi M, et al. — Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer’s disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis — Alzheimer’s & Dementia, 2024 — doi.org/10.1002/alz.14458
- Palmqvist S, et al. — Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care — JAMA, 2024 — doi.org/10.1001/jama.2024.13855
- Palmqvist S, et al. — Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform — Nature Medicine, 2025 — doi.org/10.1038/s41591-025-03622-w
- Wang J, et al. — Diagnostic accuracy of plasma p-tau217/Abeta42 for Alzheimer’s disease in clinical and community cohorts — Alzheimer’s & Dementia, 2025 — doi.org/10.1002/alz.70038
- van Dyck CH, et al. — Lecanemab in Early Alzheimer’s Disease — New England Journal of Medicine, 2023 — doi.org/10.1056/NEJMoa2212948
- Cummings J, et al. — Lecanemab: Appropriate Use Recommendations — The Journal of Prevention of Alzheimer’s Disease, 2023 — doi.org/10.14283/jpad.2023.30
Further reading
- Understand lab results: reference ranges, flags and next steps
- Diabetes: symptoms, causes and treatments
- High cholesterol: causes, symptoms and treatments
- BP meaning: a blood pressure measurement guide
- CRP: understanding your blood test results
Understand your lab results with BloodSense
Anyone investigating memory changes leaves the laboratory with a page of numbers long before any specialist appointment: thyroid stimulating hormone, vitamin B12, sodium, calcium, kidney function and a blood count. Those values are the part of the work-up that most often finds something treatable, and they are also the part patients understand least. BloodSense turns that report into clear language so you can arrive at your appointment with informed questions. It helps you understand your results; it does not diagnose Alzheimer’s disease and it does not replace your doctor.
